Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Nutrien Ltd (NTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Nutrien Ltd — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Nutrien Ltd trades at $66.04 (market cap $31.34B). The key difference: Nutrien Ltd is far larger — about 7× ACADIA Pharmaceuticals Inc.'s market cap, and Nutrien Ltd pays a 3.37% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | NTR | |
|---|---|---|
Market Cap | $4.49B | $31.34B |
Sector | Health | Basic Materials |
52-Week High | $28.06 | $83.94 |
52-Week Low | $20.06 | $53.64 |
Enterprise Value | $3.69B | $44.51B |
Dividend Yield | — | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Nutrien (NTR) trades at $65.32, up 0.4% with a bullish technical signal despite mixed moving averages. The company shows improving fundamentals with Q1 2026 earnings beating estimates and revenue growth projected to $27.8B in 2026. Analyst consensus is strongly bullish with a $81.86 price target, representing 25% upside potential from current levels.
NTR presents value with attractive valuation multiples (P/E 13.14, P/S 1.12) and strong fertilizer demand fundamentals. Key risks include volatile input costs, supply chain disruptions, and debt refinancing needs. The stock offers dividend income with recent $0.55 payout, positioning it as a compelling agribusiness investment amid global food security trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
